This is read by an automated voice. Please report any issues or inconsistencies here. I am living with ALS, or amyotrophic lateral sclerosis, often called Lou Gehrig’s disease. The average survival ...

Johns Hopkins’ Thomas Hartung discusses how drug discovery and development will change under evolving regulatory policies ...

Millions of animals each year are killed in U.S. laboratories as part of medical training and chemical, food, drug and cosmetic testing, according to the non-profit animal rights organization People ...

In a bid to prioritise more human-relevant models, the US Food and Drug Administration (FDA) has enforced a plan to phase out animal testing for monoclonal antibodies (mAbs) in the preclinical stage, ...

The Food and Drug Administration (FDA) announced Thursday it plans to phase out animal testing requirements for biological products and drugs, instead moving toward alternative testing models such ...

Please provide your email address to receive an email when new articles are posted on . The FDA plans to reduce and potentially replace animal testing for developing monoclonal antibody therapies and ...

Explore the debate surrounding animal testing as new methods may jeopardise patient safety if not properly validated.

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...

(Reuters) -Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near ...

Charles River Laboratories International, Inc. is a Hold as shares reflect both near-term headwinds & long-term disruption risks. Read more on CRL stock here.

Torie Bosch is the First Opinion editor at STAT. First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech ...